Global Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market to 2030 – Insight, Epidemiology…

first_img Facebook Previous articleFlorida, Notre Dame schedule home-and-home series in ’31-32Next articlePureFacts accélère sa croissance en recrutant une directrice en charge du développement du chiffre d’affaire expérimentée du classement “Fortune 500” Digital AIM Web Support By Digital AIM Web Support – February 9, 2021 Twitter WhatsApp DUBLIN–(BUSINESS WIRE)–Feb 9, 2021– The “Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report delivers an in-depth understanding of the AAV Vector Based Gene Therapy, historical and forecasted epidemiology as well as the AAV Vector Based Gene Therapy market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. The AAV Vector Based Gene Therapy market report provides emerging drugs, AAV Vector Based Gene Therapy market share of the individual diseases, current and forecasted AAV Vector Based Gene Therapy market size from 2017 to 2030 segmented by seven major markets. The Report also covers current AAV Vector Based Gene Therapy market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market. The AAV Vector Based Gene Therapy epidemiology division provides the insights about historical and current AAV Vector Based Gene Therapy patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Key Findings The disease epidemiology covered in the report provides historical as well as forecasted AAV Gene Therapies epidemiology [segmented as Total cases of AAV Gene Therapy Targeted Indications, Total diagnosed indication-specific cases, Number of Patients Eligible for AAV Gene Therapy and Total treated cases] scenario of AAV Gene Therapy in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030. Country Wise- AAV Vector Based Gene Therapy Epidemiology Estimates show that the highest cases of AAV vector based gene therapy in the 7MM were in the United States, followed by Germany, Japan, France, the United kingdom, Italy, and Spain in 2017. AAV vector based gene therapy Drug Chapters Drug chapter segment of the AAV vector based gene therapy report encloses the detailed analysis of AAV vector based gene therapy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the AAV vector based gene therapy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Scope of the ReportThe report covers a detailed overview of the development of AAV vectors and gene therapies based on them across the various therapeutic areas and several selected indications, explaining its various serotypes, benefits, and challenges for futureComprehensive insight has been provided into the AAV Vector Based Gene Therapy epidemiology and treatment in the 7MM.Additionally, an all-inclusive account of both the current and emerging therapies for AAV Vector Based Gene Therapy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.A detailed review of AAV Vector Based Gene Therapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.The report provides an edge while developing business strategies, by understanding trends shaping and driving the global AAV Vector Based Gene Therapy market. AAV Vector Based Gene Therapy Report InsightsPatient PopulationTherapeutic ApproachesAAV Vector Based Gene Therapy Pipeline AnalysisAAV Vector Based Gene Therapy Market Size and TrendsMarket OpportunitiesImpact of upcoming Therapies AAV Vector Based Gene Therapy Report Key Strengths11 Years Forecast7MM CoverageAAV Vector Based Gene Therapy Epidemiology SegmentationKey Cross CompetitionHighly Analyzed MarketDrugs Uptake AAV Vector Based Gene Therapy Report AssessmentSWOT AnalysisCurrent Treatment PracticesUnmet NeedsPipeline Product ProfilesConjoint AnalysisMarket AttractivenessMarket Drivers and Barriers Reasons to BuyThe report will help in developing business strategies by understanding trends shaping and driving the AAV Vector Based Gene Therapy market.To understand the future market competition in the AAV Vector Based Gene Therapy market and Insightful review of the key market drivers and barriers.Organize sales and marketing efforts by identifying the best opportunities for AAV Vector Based Gene Therapy in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.Organize sales and marketing efforts by identifying the best opportunities for AAV Vector Based Gene Therapy market.To understand the future market competition in the AAV Vector Based Gene Therapy market. Companies MentionedAmicus TherapeuticsAsklepios BiopharmaceuticalBioMarin PharmaceuticalHorama S.AMeiraGTx UK II LtdNeurocrine BiosciencesNightstaRxPfizerRocheSangamo TherapeuticsSarepta TherapeuticsSpark TherapeuticsVoyager Therapeutics For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/p3sdwo View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005920/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH GENERAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/09/2021 11:16 AM/DISC: 02/09/2021 11:16 AM http://www.businesswire.com/news/home/20210209005920/en TAGS  Facebookcenter_img Global Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market to 2030 – Insight, Epidemiology and Forecasts – ResearchAndMarkets.com Local NewsBusiness Twitter Pinterest WhatsApp Pinterestlast_img read more

Global Dry Eye Medication Market Report 2020-2030 – Major Players are Novartis, Allergan, Otsuka,…

first_img Previous articleWinning numbers drawn in ‘Two Step’ gameNext articleBringCom Completes Pan-African Fiber Ring Network Digital AIM Web Support Local NewsBusiness By Digital AIM Web Support – February 16, 2021 TAGS  DUBLIN–(BUSINESS WIRE)–Feb 16, 2021– The “Dry Eye Medication Global Market Report 2020-30: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering. The global dry eye medication market is expected to decline from $3.8 billion in 2019 to $3 billion in 2020 at a compound annual growth rate (CAGR) of -21.7%. The decline is mainly due to the COVID-19 outbreak and the measures to contain it. COVID-19 pandemic is affecting industries across the globe including the pharmaceutical sector. The restrictions on non-essential medical services including ophthalmology services coupled with slowed production of drugs due to extended factory closures in various countries, shortage of APIs and other chemicals, and rise in prices of key ingredients are the key factors for this decline. The market is then expected to recover and grow at a CAGR of 6.6% from 2021 and reach $5.1 billion in 2023. The global dry eye medication market was worth $3.95 billion in 2018. It is expected to grow at a compound annual growth rate (CAGR) of 6.14% and reach $5.32 billion by 2023. The dry eye medication market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023. The increased number of cases for dry eye disease results in the increased demand for its treatment. Factors such as aging, lack of vitamin A, wearing lenses, eye surgeries, direct contact with dry wind or smoke, and exposing one’s eyes to screens for long duration increase the occurrence of the dry eye more likely. For example, a survey conducted by the American Academy of Ophthalmology in 2015 reported that in the USA, nearly 3.2 million women and 1.68 million men, over the age of 50 were affected by dry eye syndrome. Similarly, a 2017 study conducted by Indian Journal Ophthalmology indicated a 32% prevalence of dry eye disease in the Northern part of India. Rising prevalence of the disease would increase the demand for its treatment and ultimately facilitate the growth of this market. The market for dry eye medication is restricted by the long approval process that is undertaken before any drug is approved by the concerned authority. The standard protocol for testing any new drug demands a series of tests and trials including laboratory tests, animal model tests, and clinical trials. Most drugs fail during clinical trials and only a small percent of them successfully move forward. The cumbersome process of obtaining approvals takes longer duration of time and restricts the growth of this market. For example, Xiidra, a drug for dry eyes was approved by FDA in 2016 after its safety and effectiveness were assessed on more than 1,000 adults in four different clinical trials. Similarly, Kissei Pharmaceutical announced to discontinue the development of KCT-0809 drug after it failed to pass the 3rd phase of clinical trials in 2017. Treatment for dry eye disease improved with incorporation of modern techniques that helped invent advanced hyaluronic acid-based lubricants and lipid emulsions. This technology replaces artificial tears that include isotonic sodium chloride and provide long-lasting lubrication on the surface of the eye. Major players in the market are Novartis, Allergan, Otsuka, Santen Pharmaceutical and Auven Therapeutics. Key Topics Covered: 1. Executive Summary 2. Dry Eye Medication Market Characteristics 3. Dry Eye Medication Market Size And Growth 3.1. Global Dry Eye Medication Historic Market, 2015-2019, $ Billion 3.1.1. Drivers Of The Market 3.1.2. Restraints On The Market 3.2. Global Dry Eye Medication Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers Of The Market 3.2.2. Restraints On the Market 4. Dry Eye Medication Market Segmentation 4.1. Global Dry Eye Medication Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ BillionAqueous dry eye syndromeEvaporative dry eye syndrome 4.2. Global Dry Eye Medication Market, Segmentation By end-user, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ BillionHospital PharmaciesEye Health ClinicsRetail PharmaciesOnline Pharmacies 4.3. Global Dry Eye Medication Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ BillionLiquid DropsGelLiquid WipesEye Ointment 5. Dry Eye Medication Market Regional And Country Analysis 5.1. Global Dry Eye Medication Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global Dry Eye Medication Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Companies MentionedNovartisAllerganOtsukaSanten PharmaceuticalAuven TherapeuticsAkornValent PharmaceuticalsJohnson and Johnson VisionAlconBausch & LombI-Med Pharma IncSun Pharmaceutical Industries LtdSentiss Pharma Pvt LtdReckitt Benckiser Group PLCAlcon Laboratories IncShireNicoxTheaNovaliqPfizer’s InnoPharmaAltaire Pharmaceuticals IncRaynerAFT pharmaceuticalsKala PharmaceuticalsSimilasan CorporationAbbott LaboratoriesFDC LimitedLupin LimitedOASIS Medical For more information about this report visit https://www.researchandmarkets.com/r/cu4fs6 View source version on businesswire.com:https://www.businesswire.com/news/home/20210216005567/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH OPTICAL SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/16/2021 04:47 AM/DISC: 02/16/2021 04:47 AM http://www.businesswire.com/news/home/20210216005567/en Pinterest Pinterest Facebookcenter_img Twitter Facebook WhatsApp Global Dry Eye Medication Market Report 2020-2030 – Major Players are Novartis, Allergan, Otsuka, Santen Pharmaceutical and Auven Therapeutics – ResearchAndMarkets.com WhatsApp Twitterlast_img read more